Mogadon (Nitrazepam)

Nitrazepam, the active ingredient in Mogadon, is a benzodiazepine presented as an oral dosage form for oral use. It is prescribed for the short‑term management of insomnia and anxiety in adult patients.

GNH USA supplies Mogadon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nitrazepam belongs to the benzodiazepine class and is used to treat conditions related to central nervous system hyper‑excitability. - Insomnia: helps initiate and maintain sleep during short‑term treatment. - Anxiety: reduces excessive worry and tension in acute anxiety episodes. - Sleep initiation difficulty: facilitates faster onset of sleep in patients with difficulty falling asleep.

Nitrazepam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy during daytime. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent lack of energy. - Memory impairment: difficulty recalling recent events. - Ataxia: loss of coordination and balance. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Suicidal thoughts: emergence of depressive ideation or self‑harm urges. - Paradoxical reactions: increased agitation, aggression, or anxiety. - Withdrawal seizures: risk when the drug is stopped abruptly after prolonged use. - Depression worsening: emergence of depressive symptoms.

Nitrazepam requires careful use and monitoring to minimise risks. - Abrupt discontinuation: taper the dose under medical supervision to avoid withdrawal seizures. - Elderly patients: start with the lowest effective dose due to increased sensitivity and fall risk. - Concomitant alcohol: avoid alcohol as it can potentiate sedation and respiratory depression. - Hepatic impairment: dose adjustment may be needed because the drug is metabolised in the liver. - Pregnancy and lactation: consult a specialist before use as safety data are limited. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nitrazepam can interact with several other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other CNS depressants (e.g., opioids, barbiturates): may cause profound sedation or respiratory depression. - Alcohol: additive sedative effect increasing risk of accidents. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise nitrazepam plasma levels and toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Antifungal agents (e.g., fluconazole): may modestly increase nitrazepam concentrations. - Selective serotonin reuptake inhibitors (SSRIs): may enhance central nervous system depression.